Novartis opens radioligand therapy facility in Carlsbad, US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Fenebrutinib targets cells in the immune system known as B cells and microglia
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
This partnership has led to a 10% boost in delivery speed
Subscribe To Our Newsletter & Stay Updated